Correction: Mayo Clinic, Rheonix Partner to Evaluate Warfarin Test | GenomeWeb

The story previously reported that the test being evaluated is from Rheonix and is based on its CARD technology. In fact, Mayo is developing its own test based on IP from Rheonix but not based on the CARD technology.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Mayo Clinic said on Monday that it has reached an agreement with Rheonix to collaborate on evaluating the performance of a genotyping test for warfarin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.